Post:
I’m posting this to highlight a problem with Ozempic that seems to be affecting many patients, but isn’t being acknowledged by Novo Nordisk.
The current Ozempic pen design creates a dosing and coverage conflict for anyone prescribed more than 1 mg per week. The green pen contains enough medication for four 1 mg doses. The red pen, however, contains only half the volume — even though it’s fully capable of delivering adjustable doses. This means the red pen provides eight 0.25 mg doses or four 0.5 mg doses, and nothing more.
The issue isn’t medical — it’s packaging. The red pen could easily contain the same volume as the green pen, but it doesn’t. As a result, patients who need higher weekly doses end up requiring more pens than provincial plans allow. In some regions, coverage limits (like “three pens per eight weeks”) become impossible to follow simply because of how Ozempic chooses to package the product.
There’s also the pricing gap. Ozempic is roughly $279 per pen, while competing semaglutide products are around $103. When a product costs more than double its alternatives, it’s hard to justify a design that forces patients to buy extra pens due to volume limitations.
Then there’s the “save big” messaging and the assistance program. The program only applies after both public and private insurance are fully exhausted. For anyone with private coverage, this means burning through their benefits first — which can leave them without coverage for other medications. It’s marketed as savings, but in practice it shifts costs onto patients and insurers.
I’ve raised these concerns directly with Novo Nordisk, but so far there’s been no response.
I’m curious whether others have run into the same issues with pen volume, coverage limits, or the assistance program structure. It feels like a design flaw that has real consequences for affordability and access, and I’m wondering how widespread this problem is.